NDC 65302-042-01 - Budesonide Inhalation
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 65302-042
- Requested NDC
- 65302-042-01
- Package NDCs from labels
- 65302-042-01
- Manufacturer
- The Ritedose Corporation
- Effective date
- 2019-12-20
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Budesonide Inhalation Suspension - The Ritedose Corporation | The Ritedose Corporation | 2019-12-20 | HUMAN PRESCRIPTION DRUG LABEL |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| DEXTROSE AND SODIUM CHLORIDE | DEXTROSE MONOHYDRATE, SODIUM CHLORIDE | Fresenius Kabi USA, LLC | b825c9c4-f2fb-4a4a-9d8c-fb020ad07e93 | 2020-04-30 | Warnings, Adverse reactions | 451W47IQ8X |
| Uceris | BUDESONIDE | Salix Pharmaceuticals, Inc. | 230e4596-2a9b-4d55-b0a0-0cabbcff5289 | 2020-04-23 | Warnings, Adverse reactions | Q3OKS62Q6X |
| 0.9% SODIUM CHLORIDE | 0.9% SODIUM CHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | a2b8220f-e33a-51c3-e053-2995a90a0734 | 2020-04-07 | Warnings, Adverse reactions | 451W47IQ8X |
| 0.9% SODIUM CHLORIDE | 0.9% SODIUM CHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | a2bba76a-08ce-6902-e053-2995a90ab9c9 | 2020-04-07 | Warnings, Adverse reactions | 451W47IQ8X |
| Dextrose and Electrolyte No. 48 | SODIUM LACTATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, MONOBASIC POTASSIUM PHOSPHATE, SODIUM CHLORIDE AND DEXTROSE MONOHYDRATE | Baxter Healthcare Company | b283a454-0c20-4fbf-92d3-dae1f3cd3cad | 2020-02-13 | Warnings, Adverse reactions | 451W47IQ8X |
| Sodium Chloride | SODIUM CHLORIDE | Baxter Healthcare Corporation | fbc01464-8885-4075-af41-911ffec5ae92 | 2020-01-27 | Warnings, Adverse reactions | 451W47IQ8X |
| Sterile Water | WATER | Baxter Healthcare Company | 8bcf5572-49e1-4302-9522-56f57904cb4a | 2019-12-29 | Warnings, Adverse reactions | 059QF0KO0R |
| 9a27fc4e-5c1e-9e9b-e053-2995a90aaa20 | 9a27fc4e-5c1d-9e9b-e053-2995a90aaa20 | 2019-12-20 | 9a27fc4e-5c1e-9e9b-e053-2995a90aaa20 9a27fc4e-5c1d-9e9b-e053-2995a90aaa20 | |||
| Renacidin | CITRIC ACID, GLUCONOLACTONE AND MAGNESIUM CARBONATE | United-Guardian, Inc. | 13a9bbba-db21-4cba-991c-5d8afaf2ed74 | 2019-12-17 | Warnings, Adverse reactions | XF417D3PSL |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | e41adb4e-06fb-4141-ba55-50b043f3c9da | 2019-11-19 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 14445dfd-6041-40cd-a043-3f4da6bcb9c1 | 2019-11-18 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 2557199a-5f60-49d8-b093-1e0700211243 | 2019-11-18 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 794f724c-87f0-49c1-9b26-c9e491978313 | 2019-11-18 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 5c7d3287-883a-459b-9214-074a583c8a59 | 2019-11-18 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 448a1dc5-7a98-4b2f-82af-4b92de05cfc3 | 2019-11-18 | XF417D3PSL | |
| Budesonide | BUDESONIDE | Teva Pharmaceuticals USA, Inc. | d90ffda1-12c7-4726-90e9-64bb103e84b5 | 2019-10-31 | Warnings, Adverse reactions | Q3OKS62Q6X |
| PULMICORT RESPULES | BUDESONIDE | AstraZeneca Pharmaceuticals LP | 33cd9834-76df-4f26-3fa2-aab6b9eee8f2 | 2019-10-11 | Warnings, Adverse reactions | Q3OKS62Q6X |
| Plasma-Lyte A | SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE AND MAGNESIUM CHLORIDE | Baxter Healthcare Corporation | 6ec9e61c-2c26-402f-8604-f446b2e34058 | 2019-08-05 | Warnings, Adverse reactions | 451W47IQ8X |
| SYMBICORT | BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE | AstraZeneca Pharmaceuticals LP | fafa4cf1-99c2-43d5-73ad-51f256de3be0 | 2019-07-24 | Warnings, Adverse reactions | Q3OKS62Q6X |
| Budesonide and Formoterol Fumarate Dihydrate | BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE | AstraZeneca Pharmaceuticals LP | 1d266fe8-52e3-4f85-a037-c5c1afa15e60 | 2019-07-24 | Warnings, Adverse reactions | Q3OKS62Q6X |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.